Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy

• Status: Unknown status
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary endpoint: virological success (HIV RNA <50 copies/mL) in the first six months and at the end of the study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UPECLIN HC FM Botucatu Unesp
• Treatments: Anti-Retroviral Agents; Efavirenz; Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• HIV-1 infected naive-treatment patients

Exclusion Criteria:

• use of Anti-Retroviral Agents in the past